 Christina Finlayson
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2017 | 2253 | 0.970 |
Why?
| | Carcinoma, Ductal, Breast | 5 | 2017 | 83 | 0.490 |
Why?
| | Mastectomy, Segmental | 5 | 2017 | 93 | 0.380 |
Why?
| | Receptors, Estrogen | 7 | 2012 | 436 | 0.330 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 115 | 0.300 |
Why?
| | Lymph Nodes | 3 | 2007 | 491 | 0.300 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 77 | 0.270 |
Why?
| | Mammography | 1 | 2007 | 154 | 0.250 |
Why?
| | Prostheses and Implants | 1 | 2007 | 143 | 0.250 |
Why?
| | Receptors, Progesterone | 4 | 2012 | 350 | 0.220 |
Why?
| | src Homology Domains | 1 | 2003 | 41 | 0.210 |
Why?
| | Receptor, ErbB-2 | 3 | 2012 | 341 | 0.210 |
Why?
| | Mastectomy | 3 | 2007 | 137 | 0.200 |
Why?
| | Preoperative Care | 2 | 2001 | 362 | 0.190 |
Why?
| | Estrogens | 3 | 2012 | 367 | 0.190 |
Why?
| | Patients | 1 | 2001 | 175 | 0.160 |
Why?
| | Mammaplasty | 1 | 2001 | 105 | 0.160 |
Why?
| | Vitamin E | 1 | 2000 | 124 | 0.160 |
Why?
| | Phytotherapy | 1 | 2000 | 83 | 0.160 |
Why?
| | Postoperative Hemorrhage | 1 | 2000 | 86 | 0.160 |
Why?
| | Counseling | 1 | 2001 | 391 | 0.150 |
Why?
| | Neoplasm Staging | 8 | 2010 | 1389 | 0.140 |
Why?
| | Reoperation | 2 | 2017 | 573 | 0.140 |
Why?
| | Tamoxifen | 5 | 2012 | 202 | 0.140 |
Why?
| | Pelvic Exenteration | 1 | 1996 | 11 | 0.130 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 92 | 0.130 |
Why?
| | Pelvic Neoplasms | 1 | 1996 | 26 | 0.130 |
Why?
| | Neoadjuvant Therapy | 3 | 2010 | 404 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 118 | 0.120 |
Why?
| | Carcinoma, Lobular | 2 | 2017 | 49 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2016 | 138 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 220 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2012 | 161 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2010 | 1396 | 0.100 |
Why?
| | Insulin | 1 | 2003 | 2409 | 0.100 |
Why?
| | Signal Transduction | 3 | 2012 | 5079 | 0.100 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.100 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2008 | 220 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1313 | 0.090 |
Why?
| | Breast | 2 | 2003 | 151 | 0.090 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 49 | 0.090 |
Why?
| | Female | 23 | 2017 | 73304 | 0.090 |
Why?
| | Axilla | 2 | 2007 | 47 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1587 | 0.080 |
Why?
| | Keratin-5 | 1 | 2010 | 50 | 0.080 |
Why?
| | Radiotherapy | 2 | 2008 | 201 | 0.080 |
Why?
| | Palliative Care | 1 | 1996 | 758 | 0.080 |
Why?
| | BRCA2 Protein | 1 | 2009 | 63 | 0.080 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 52 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 145 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.080 |
Why?
| | Middle Aged | 14 | 2017 | 33479 | 0.080 |
Why?
| | Humans | 30 | 2017 | 137585 | 0.070 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 54 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 801 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 226 | 0.070 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 130 | 0.070 |
Why?
| | Breast Cyst | 1 | 2006 | 2 | 0.070 |
Why?
| | Cyst Fluid | 1 | 2006 | 25 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2007 | 81 | 0.070 |
Why?
| | Sternum | 1 | 2006 | 24 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2010 | 1276 | 0.060 |
Why?
| | Melatonin | 1 | 2006 | 150 | 0.060 |
Why?
| | Phosphoproteins | 2 | 2008 | 338 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 11 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2005 | 112 | 0.060 |
Why?
| | Adult | 12 | 2017 | 37929 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 840 | 0.060 |
Why?
| | Combined Modality Therapy | 4 | 2008 | 1236 | 0.050 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 11 | 0.050 |
Why?
| | Oncogene Protein v-akt | 1 | 2003 | 24 | 0.050 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2003 | 59 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 2006 | 247 | 0.050 |
Why?
| | Receptor, Insulin | 1 | 2003 | 105 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 86 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 455 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2009 | 786 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2017 | 15657 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 545 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 267 | 0.050 |
Why?
| | Urachus | 1 | 2002 | 1 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 313 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 786 | 0.050 |
Why?
| | Aged | 6 | 2017 | 23961 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 1079 | 0.040 |
Why?
| | Mastectomy, Radical | 1 | 2000 | 4 | 0.040 |
Why?
| | Nurse Anesthetists | 1 | 2000 | 3 | 0.040 |
Why?
| | Prospective Studies | 2 | 2003 | 7604 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2691 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1759 | 0.040 |
Why?
| | Gynecomastia | 1 | 1998 | 6 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 499 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2002 | 252 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2008 | 1738 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 1998 | 35 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2000 | 255 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 767 | 0.040 |
Why?
| | Survival Rate | 2 | 2008 | 1972 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 50 | 0.030 |
Why?
| | Apoptosis | 2 | 2010 | 2553 | 0.030 |
Why?
| | Gene Expression Profiling | 3 | 2008 | 1774 | 0.030 |
Why?
| | Ultrasonography | 1 | 2000 | 759 | 0.030 |
Why?
| | Estradiol | 2 | 2010 | 521 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 307 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2010 | 7635 | 0.030 |
Why?
| | Decision Making | 1 | 2001 | 900 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 683 | 0.030 |
Why?
| | Lymph Node Excision | 2 | 2009 | 171 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2000 | 940 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 556 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 20 | 0.020 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 102 | 0.020 |
Why?
| | Patient Selection | 1 | 1996 | 696 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 367 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 309 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1996 | 1050 | 0.020 |
Why?
| | Colorado | 2 | 2017 | 4565 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 3412 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 189 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 601 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 955 | 0.020 |
Why?
| | Mass Screening | 1 | 1998 | 1287 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 305 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2010 | 64 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 114 | 0.020 |
Why?
| | Prognosis | 2 | 2009 | 4030 | 0.020 |
Why?
| | Databases, Protein | 1 | 2010 | 85 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 144 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 80 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 872 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 343 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 247 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 140 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 188 | 0.020 |
Why?
| | Databases as Topic | 1 | 2008 | 67 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 510 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 399 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 63 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 107 | 0.020 |
Why?
| | Mastectomy, Modified Radical | 1 | 2007 | 6 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 362 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 317 | 0.020 |
Why?
| | SEER Program | 1 | 2008 | 227 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2007 | 29 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2008 | 352 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1226 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 56 | 0.020 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2006 | 46 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 698 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2006 | 177 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 971 | 0.020 |
Why?
| | Neoplasms | 1 | 2000 | 2671 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 294 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 434 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 157 | 0.010 |
Why?
| | Quality of Life | 1 | 1996 | 2892 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 480 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 389 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 771 | 0.010 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 2129 | 0.010 |
Why?
| | Proteomics | 1 | 2010 | 1111 | 0.010 |
Why?
| | Mice | 2 | 2012 | 17787 | 0.010 |
Why?
| | Postmenopause | 1 | 2005 | 366 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1483 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10811 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2475 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 985 | 0.010 |
Why?
| | Umbilicus | 1 | 2002 | 18 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2002 | 39 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3284 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3196 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 1129 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 3295 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1943 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1692 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 12 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 11 | 0.010 |
Why?
| | United States | 1 | 2017 | 14841 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2000 | 164 | 0.010 |
Why?
| | Male | 4 | 2012 | 67762 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 182 | 0.010 |
Why?
| | Leydig Cell Tumor | 1 | 1998 | 8 | 0.010 |
Why?
| | Animals | 2 | 2012 | 36940 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6079 | 0.010 |
Why?
| | Testicular Neoplasms | 1 | 1998 | 110 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 6763 | 0.010 |
Why?
| | NF-kappa B | 1 | 2000 | 691 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 591 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 1999 | 1289 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2000 | 1242 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 766 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 10388 | 0.010 |
Why?
| | Models, Biological | 1 | 2000 | 1783 | 0.010 |
Why?
| | Adolescent | 1 | 1998 | 21513 | 0.000 |
Why?
|
|
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|